1.Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(8):635-640
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
.
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Drug Resistance, Neoplasm
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Molecular Targeted Therapy
;
methods
;
Mutation
;
Proto-Oncogene Proteins B-raf
;
genetics
2.Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer.
Peng SONG ; Li ZHANG ; Congcong SHANG
Chinese Journal of Lung Cancer 2018;21(9):703-711
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
Drug Resistance, Neoplasm
;
genetics
;
Gene Fusion
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
;
Receptor Protein-Tyrosine Kinases
;
antagonists & inhibitors
;
genetics
3.Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on the Risk of Lung Cancer and the Clinical Response to Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
Ning ZHU ; Yi GONG ; Jian HE ; Jingwen XIA ; Xiaodong CHEN
Yonsei Medical Journal 2013;54(6):1384-1393
PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). However, the results are controversial. We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC. MATERIALS AND METHODS: The databases of PubMed, Ovid, Wanfang and Chinese Biomedicine were searched for eligible studies. Nineteen studies on MTHFR C677T polymorphism and lung cancer risk and three articles on C677T polymorphism and response to platinum-based chemotherapy in advanced NSCLC, were identified. RESULTS: The results indicated that the allelic contrast, homozygous contrast and recessive model of the MTHFR C677T polymorphism were associated significantly with increased lung cancer risk. In the subgroup analysis, the C677T polymorphism was significantly correlated with an increased risk of NSCLC, with the exception of the recessive model. The dominant model and the variant T allele showed a significant association with lung cancer susceptibility of ever smokers. Male TT homozygote carriers had a higher susceptibility, but the allelic contrast and homozygote model had a protective effect in females. No relationship was observed for SCLC in any comparison model. In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model. CONCLUSION: The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum-based chemotherapy in advanced NSCLC. However, our results require further verification.
Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics
;
Genetic Predisposition to Disease
;
Humans
;
Lung Neoplasms/drug therapy/*enzymology/*genetics
;
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
;
Platinum/*therapeutic use
;
Polymorphism, Genetic/genetics
4.Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation.
Chinese Journal of Lung Cancer 2019;22(5):324-328
With the development of sequencing technology, the detection rate of de novo T790M mutation is increasing. The emergence of the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide treatment opportunities. Secondary T790M mutation is often emphasized in clinic, but de novo T790M mutation is neglected. This review found that the incidence of de novo T790M mutation fluctuated greatly, which was mainly affected by sequencing techniques. The de novo T790M mutation is mainly low in mutation abundance, easy to combine with other gene changes, a poor predictor and prognostic factor and the efficacy of the first and second generation EGFR-TKIs is limited. The therapeutic value of osimertinib needs to be studied.
.
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
drug therapy
;
enzymology
;
genetics
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Humans
;
Lung Neoplasms
;
diagnosis
;
drug therapy
;
enzymology
;
genetics
;
Mutation
;
Prognosis
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
5.Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients.
Hui LI ; Shi YAN ; Xianhong LIU ; Ying LIU ; Lixia MA ; Ying WANG ; Yan LIU ; Ying CHENG
Chinese Journal of Lung Cancer 2018;21(11):821-827
BACKGROUND:
Epidermal growth factor receptor (EGFR)-based targeted therapy improves the survival of patients with advanced lung adenocarcinoma harboring EGFR mutations. However, factors including treatment or heterogeneity partly contribute to EGFR genetic status alteration between baseline and disease progresses (PD). The aim of this study is to compare difference of EGFR mutations between biopsy and rebiopsy in real world.
METHODS:
Data from 61 paired specimens performed EGFR testing in Jilin Provincial Cancer Hospital between January 2015 and December 2017 were collected and analyzed. The specimens were collected at baseline and PD, confirmed by histology or cytology and categorized as tumor tissue, malignant pleural effusion or plasma. All patients were naive and received chemotherapy or targeted therapy as first-line treatment. Amplification Refractory Mutation System (ARMS) was used to detect EGFR mutations.
RESULTS:
EGFR mutation rate in tumor tissue, pleural effusion or blood was 90.2% vs 88.5%, 6.6% vs 6.6% and 3.2% vs 4.9% at baseline or PD respectively and discrepancy was 72% and 36.3% for the same (n=50) or different (n=11) type of specimens. The EGFR mutation rate was 95.1% and 91.8% in patients before and after treatment, and the discrepancy was 63.9%, among which, 69.2% and 92.3% in chemotherapy-treated patients (n=13) with discrepancy to 46.1% (6/13), and 100.0% and 91.7% in EGFR-TKI-treated patients (n=48) with discrepancy to 70.8%. There were four types of alterations in terms of EGFR mutations: wild type turned into mutation (4.9%), mutation disappeared (8.2%), sensitive mutations transformed (1.6%), and new mutations appeared (49.1%).
CONCLUSIONS
In real world, the EGFR mutation status in advanced non-small cell lung cancer (NSCLC) patients altered significantly, due to tissue resources and therapeutic approaches, implying the importance of rebiopsy and real-time detection of EGFR mutation, in order to provide data to guide precise strategy in the following treatment.
Adult
;
Aged
;
Biopsy
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Male
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
therapeutic use
;
Retrospective Studies
;
Treatment Outcome
6.A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib.
Yudong SU ; Zhaoting MENG ; Xiaoyan XU ; XinYue WANG ; Ran ZUO ; Yunxia HOU ; Kai LI ; Peng CHEN
Chinese Journal of Lung Cancer 2018;21(5):428-430
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.
.
Adenocarcinoma
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Adenocarcinoma of Lung
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Humans
;
Indoles
;
therapeutic use
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Male
;
Mutation
;
Proto-Oncogene Proteins p21(ras)
;
genetics
;
metabolism
;
Quinolines
;
therapeutic use
7.Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor.
Ya-Li LIU ; Ying WANG ; Jia-Li YI ; Huan JING ; Chun-Ying LIU
China Journal of Chinese Materia Medica 2014;39(10):1869-1873
OBJECTIVETo explore the effect of Buzhong Yiqi decoction on PI3K/AKT signaling pathway in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor.
METHODTotally 60 nude mice were randomly divided into the blank control group, the tumor-bearing control group, the cisplatin group, the low-dose Buzhong Yiqi decoction group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. After the corresponding interventions, efforts were made to measure the transplanted tumor volume and calculate the tumor inhibiting rate. The immunohistochemical method and real time PCR were used to detect the expression of PI3K and AKT level in nude mice spleen, stomach and lung.
RESULTBuzhong Yiqi decoction of different concentrations combined with cisplatin could inhibit the growth of the transplanted tumor, with the strongest inhibitory effect in the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group. All of the expressions of PI3K and AKT protein and gene in the spleen, stomach and lung increased, with the most significant increase in the tumor-bearing group. Along with the increase of the concentration of cisplatin and Buzhong Yiqi decoction, the expressions of PI3K and AKT gradually reduced. Compared with the tumor-bearing control group, there were statistical differences in spleen and stomach tissues (P < 0.05). Compared with the cisplatin group, the middle-dose Buzhong Yiqi decoction group and the high-dose Buzhong Yiqi decoction group showed statistical differences (P < 0.05), but without statistical difference compared with the blank control group.
CONCLUSIONAmong nude mice with lung adenocarcinoma transplantation tumor, the PI3K and AKT protein and gene expressions in spleen, stomach and lung tissues increased, which might indicated the effect of cisplatin and Buzhong Yiqi decoction in reducing PI3K and AKT expressions and the relations between the reduction degree and the concentrations of Buzhong Yiqi decoction. Cisplatin combined with Buzhong Yiqi decoction could decrease the PI3K and AKT protein and gene expression in spleen, stomach and lung, and make the pathway closer to normal, so as to protect the functions of spleen, stomach and lung, there may be target spots of Buzhong Yiqi decoction in PI3K/AKT signal pathway.
Adenocarcinoma ; drug therapy ; enzymology ; genetics ; Animals ; Cell Line, Tumor ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Lung ; drug effects ; enzymology ; Lung Neoplasms ; drug therapy ; enzymology ; genetics ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oncogene Protein v-akt ; genetics ; metabolism ; Phosphatidylinositol 3-Kinases ; genetics ; metabolism ; Signal Transduction ; drug effects ; Spleen ; drug effects ; enzymology
8.EGFR-TKI ADR Management Chinese Expert Consensus.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
Chinese Journal of Lung Cancer 2019;22(2):57-81
ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China. And osimertinib was approved in second line setting for patients with EGFRT 790M-positive NSCLC. Rash, paronychia, diarrhea, stomatitis, liver dysfunction and (interstitial lung disease, ILD) are frequently observed in patients treated with EGFR-TKI. Chinese Society of Lung Cancer, Chinese Anti-Cancer Association, organized Chinese experts to develop the Chinese expert consensus on EGFR-TKI adverse event (AE) management based on domestic diagnosis and treatment of ADR and also incorporating international updated theory and recommendations.
.
Antineoplastic Agents
;
adverse effects
;
therapeutic use
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
China
;
Diarrhea
;
etiology
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Humans
;
Liver Diseases
;
etiology
;
Lung Diseases
;
etiology
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Protein Kinase Inhibitors
;
adverse effects
;
therapeutic use
;
Stomatitis
;
etiology
9.Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy in Advanced NSCLC Patients with EGFR Mutations.
Minjiang CHEN ; Yan XU ; Jing ZHAO ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(2):99-104
BACKGROUND:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated some dramatic efficacy in advanced non-small-cell lung cancer (NSCLC) patients with activating EGFR mutation. However, progression-free survivals (PFS) among those patients who were treated with first line EGFR TKIs were inconsistent. The aim of this study is to explore the association of clinical prognostic factors with EGFR-TKI efficacy in advanced NSCLC patients.
METHODS:
The demographic and clinical characteristics of 203 patients with activating EGFR mutation treated with first generation TKI as a first-line therapy were retrospectively reviewed.
RESULTS:
Of the 203 patients enrolled in this study, 139 patients had progression of disease and 63 patients died. The subjects had a median follow up duration of 21.1months and a median PFS of 14.3 months. Partial response (PR) was achieved in 127 (66.1%) patients and stable disease (SD) rate was achieved in 55 (28.6%) patients. In univariate analysis, patients with 2 or higher ECOG score (5.1 vs 16 months, P=0.033), SD as best overall response (9.5 vs 17.9 months, P=0.030), extrathoracic metastasis (11.7 vs 27.5 months, P=0.004), liver metastasis (4.1 vs 16.0 months, P=0.000), bone metastasis (13.3 vs 21.5months, P=0.027) and pulmonary embolism (5.5 vs 16.6 months, P=0.005) had shorter PFS than those without the listed factors. Multivariable Cox regression analysis showed best overall response (HR=1.825, 95%CI: 1.107-3.008, P=0.018) and liver metastasis (HR=1.694, 95%CI: 1.146-5.756, P=0.022) were independent predictive factors of shorter PFS.
CONCLUSIONS
Despite the high efficacy of EGFR-TKI, SD as best overall response and liver metastasis predicts poorer PFS in advanced NSCLC patients with EGFR gene mutations receiving first-line therapy treatment.
Adult
;
Aged
;
Antineoplastic Agents
;
administration & dosage
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
mortality
;
ErbB Receptors
;
genetics
;
metabolism
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
administration & dosage
;
Retrospective Studies
;
Treatment Outcome
;
Young Adult
10.Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model.
Bin LUO ; Zu-Jun QUE ; Zhi-Yi ZHOU ; Qing WANG ; Chang-Sheng DONG ; Yi JIANG ; Bing HU ; Hui SHI ; Yu JIN ; Jian-Wen LIU ; He-Gen LI ; Lin WANG ; Jian-Hui TIAN
Journal of Integrative Medicine 2018;16(4):283-289
OBJECTIVEEscape from the body's immune response is a basic characteristic of lung cancer, and indoleamine-2,3-dioxygenase (IDO) plays a key role in mediating immune escape of non-small-cell lung cancer, which leads to recurrence and metastasis. Feiji Recipe, a compound Chinese herbal medicine, has the effect of stabilizing lesions and prolonging survival in patients with lung cancer. The purpose of this study was to investigate the mechanisms underlying the anticancer properties of Feiji Recipe.
METHODSAn orthotopic transplant model of mouse Lewis lung cancer, with stable expression of IDO gene, was established in C57BL/6 mice. Optical imaging was used to observe the effects of Feiji Recipe in the treatment of lung cancer in vivo. The effects of Feiji Recipe on the proliferation of mouse Lewis lung cancer cell line 2LL, 2LL-enhanced green fluorescent protein (2LL-EGFP) and 2LL-EGFP-IDO were investigated, and the apoptosis of T-cells was examined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide using flow cytometry. Chemical composition of Feiji Recipe was validated by high-performance liquid chromatography.
RESULTSCompared to the control group, the survival of animals treated with Feiji Recipe was significantly prolonged (P = 0.0074), and the IDO protein level decreased (P = 0.0072); moreover, the percentages of CD4CD25 T-cells and Foxp3 T-cells were significantly decreased (P < 0.05). The molecular mechanism of Feiji Recipe against lung cancer may relate to the regulation of immune cells, such as T-cells and regulatory T-cells.
CONCLUSIONThe molecular mechanism of Feiji Recipe in treatment of lung cancer is to restore the function of T-cells in the cancer microenvironment through interfering with the IDO pathway.
Animals ; Apoptosis ; drug effects ; Carcinoma, Lewis Lung ; drug therapy ; enzymology ; immunology ; physiopathology ; Cell Proliferation ; drug effects ; Disease Models, Animal ; Drugs, Chinese Herbal ; administration & dosage ; Growth Inhibitors ; administration & dosage ; Humans ; Indoleamine-Pyrrole 2,3,-Dioxygenase ; genetics ; immunology ; Lung Neoplasms ; drug therapy ; enzymology ; immunology ; physiopathology ; Male ; Mice ; Mice, Inbred C57BL ; T-Lymphocytes, Regulatory ; drug effects ; immunology